NewBiotics Inc. Appoints New President
SAN DIEGO, Calif-NewBiotics, Inc announced January 8, that H. Michael Shepard, will be the company's president.
Shepard will be responsible for overseeing all aspects of the company's research and development strategies, scientific and corporate collaborations, and related activities.
NewBiotics, a developer of drugs targeted against cancer and infectious disease, is privately held. The company's drugs use a "Trojan horse solution" to fight various diseases.
Shepard, who previously worked for Canji, and Genentech, helped develop the p53gene product for cancer therapy.
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.
